GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY24 results · Jan–Mar 2024
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹929.80 crore (up 18.1% from Q4 FY23) and net profit of ₹194.48 crore (up 45.8% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 929.80 | 787.45 | +18.1% | 805.26 | +15.5% |
| Other income | 29.83 | 27.66 | +7.8% | 28.11 | +6.1% |
| Total income | 959.63 | 815.11 | +17.7% | 833.37 | +15.2% |
| Profit before tax | 270.62 | 189.97 | +42.5% | 65.43 | +313.6% |
| Net profit for the period | 194.48 | 133.43 | +45.8% | 45.72 | +325.4% |
| EPS, basic (₹) | 11.48 | 7.88 | +45.7% | 9.89 | +16.1% |
| Net margin (%) | 20.9 | 16.9 | 5.7 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 910.87 | 782.16 | +16.5% | 804.98 | +13.2% |
| Other income | 29.87 | 27.97 | +6.8% | 28.34 | +5.4% |
| Total income | 940.74 | 810.13 | +16.1% | 833.32 | +12.9% |
| Profit before tax | 268.71 | 187.30 | +43.5% | 65.11 | +312.7% |
| Net profit for the period | 193.08 | 131.48 | +46.9% | 45.49 | +324.4% |
| EPS, basic (₹) | 11.39 | 7.77 | +46.6% | 9.88 | +15.3% |
| Net margin (%) | 21.2 | 16.8 | 5.7 |
Consolidated
- Filed with BSE
- 18 May 2024, 12:22 IST
- Board meeting
- 17 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2024, 12:22 IST
- Board meeting
- 17 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE